PCI for stable coronary disease [7]

New England Journal of Medicine

Volumn 357, Issue 4, 2007, Pages 417-

  Mak, Koon Hou ^a  

^a GLENEAGLES HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

CORONARY STENT; DEATH; HEART INFARCTION; HUMAN; INCIDENCE; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; STROKE; TREATMENT DURATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 34547181402     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized control trial. JAMA 2002;288:2411-20. [Erratum, JAMA 2003;289:987.]